NASDAQ:KZR Kezar Life Sciences (KZR) Stock Forecast, Price & News $1.14 -0.03 (-2.56%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.1950-Day Range$1.14▼$2.4252-Week Range$1.09▼$9.00Volume432,572 shsAverage Volume413,879 shsMarket Capitalization$82.87 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Kezar Life Sciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,259.6% Upside$15.50 Price TargetShort InterestHealthy3.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.66Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.38) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector201st out of 963 stocksPharmaceutical Preparations Industry79th out of 458 stocks 3.2 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Kezar Life Sciences has a forecasted upside of 1,259.6% from its current price of $1.14.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.30% of the outstanding shares of Kezar Life Sciences have been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kezar Life Sciences has recently decreased by 2.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kezar Life Sciences is -0.85. Previous Next 3.1 News and Social Media Coverage News SentimentKezar Life Sciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.Search Interest3 people have searched for KZR on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions86.83% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.38) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kezar Life Sciences (NASDAQ:KZR) StockKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More KZR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZR Stock News HeadlinesSeptember 21, 2023 | msn.comKezar and Everest enter lupus nephritis therapy development dealSeptember 20, 2023 | marketwatch.comKezar Life Sciences Shares Rise After Deal With Everest MedicinesSeptember 24, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 20, 2023 | businesswire.comKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China ...September 20, 2023 | finance.yahoo.comKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaAugust 14, 2023 | 247wallst.comWells Fargo Downgrades Kezar Life SciencesAugust 12, 2023 | msn.comWells Fargo Downgrades Kezar Life Sciences (KZR)August 11, 2023 | marketwatch.comKezar Life Sciences Down 25% After 2Q Results, Drug UpdatesSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 11, 2023 | finance.yahoo.comKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateJune 23, 2023 | fool.comKezar Life Sciences (NASDAQ: KZR)May 31, 2023 | finance.yahoo.comKezar Life Sciences to Participate in the Jefferies Healthcare ConferenceMay 13, 2023 | marketwatch.com8-K: Kezar Life Sciences, Inc.May 12, 2023 | msn.comWells Fargo Maintains Kezar Life Sciences (KZR) Overweight RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Maintains Kezar Life Sciences (KZR) Buy RecommendationMay 12, 2023 | msn.comKezar Life Sciences: Q1 Earnings InsightsMay 11, 2023 | seekingalpha.comKezar Life Sciences GAAP EPS of -$0.31May 11, 2023 | finance.yahoo.comKezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateMarch 16, 2023 | msn.comWilliam Blair Downgrades Kezar Life Sciences (KZR)March 16, 2023 | seekingalpha.comKezar sheds 14% after R&D event as William Blair downgradesMarch 14, 2023 | finance.yahoo.comKezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateMarch 13, 2023 | finance.yahoo.comKezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023March 6, 2023 | finance.yahoo.comKezar Life Sciences to Host Virtual R&D Day on March 22, 2023March 1, 2023 | finance.yahoo.comKezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 23, 2023 | seekingalpha.comKZR Kezar Life Sciences, Inc.January 4, 2023 | finance.yahoo.comKezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)See More Headlines Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KZR Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$18.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+1,259.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.81% Return on Assets-28.66% Debt Debt-to-Equity Ratio0.04 Current Ratio17.73 Quick Ratio17.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.95 per share Price / Book0.29Miscellaneous Outstanding Shares72,690,000Free Float66,950,000Market Cap$82.87 million OptionableNot Optionable Beta0.16 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. John Franklin Fowler (Age 50)Co-Founder, CEO & Director Comp: $919.91kDr. Christopher J. Kirk Ph.D. (Age 50)Co-Founder & Director Comp: $677.41kDr. Noreen Roth Henig M.D. (Age 58)Chief Medical Officer Comp: $722.85kDr. Jack Taunton Ph.D.Co-FounderMr. Marc L. Belsky (Age 68)CFO & Sec. Ms. Gitanjali JainVP of Investor Relations & External AffairsMr. Mark SchillerSr. VP of Legal AffairsDr. Neel K. Anand Ph.D.Sr. VP of Research & Drug DiscoveryDr. Nick Mordwinkin Ph.D. (Age 42)Pharm.D., Chief Bus. Officer Mr. Zung ToSr. VP of Clinical Devel. OperationsMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMCytomX TherapeuticsNASDAQ:CTMXWerewolf TherapeuticsNASDAQ:HOWLIO BiotechNASDAQ:IOBTBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInsiders & InstitutionsBarclays PLCSold 814,809 shares on 9/21/2023Ownership: 0.020%California State Teachers Retirement SystemSold 40,800 shares on 8/21/2023Ownership: 0.033%Nuveen Asset Management LLCSold 236,191 shares on 8/16/2023Ownership: 0.434%Point72 Middle East FZEBought 13,242 shares on 8/15/2023Ownership: 0.052%Y Intercept Hong Kong LtdSold 16,515 shares on 8/15/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions KZR Stock - Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares. View KZR analyst ratings or view top-rated stocks. What is Kezar Life Sciences' stock price forecast for 2023? 3 brokers have issued twelve-month target prices for Kezar Life Sciences' shares. Their KZR share price forecasts range from $13.00 to $18.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,259.6% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts. How have KZR shares performed in 2023? Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR shares have decreased by 83.8% and is now trading at $1.14. View the best growth stocks for 2023 here. When is Kezar Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our KZR earnings forecast. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO. What is Kezar Life Sciences' stock symbol? Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR." Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.86%), BlackRock Inc. (7.03%), Prosight Management LP (6.40%), Sphera Funds Management LTD. (2.74%), Granahan Investment Management LLC (2.61%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kezar Life Sciences' stock price today? One share of KZR stock can currently be purchased for approximately $1.14. How much money does Kezar Life Sciences make? Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $82.87 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. How can I contact Kezar Life Sciences? Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com. This page (NASDAQ:KZR) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.